Entries |
Document | Title | Date |
20080269181 | METHODS FOR TREATING A POSTERIOR SEGMENT OF AN EYE - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time. | 10-30-2008 |
20080275014 | Clobetasol Propionate Shampoos for the Treatment of Seborrheic Dermatitis of the Scalp - Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith. | 11-06-2008 |
20080306039 | Loteprednol Etabonate Aqueous Suspension - An aqueous suspension containing loteprednol etabonate wherein sedimented particles are detached easily from the container and adhesion of sedimented particles to the container and block formation are inhibited so that redispersion has been improved is provided. A method for improving redispersibility of loteprednol etabonate contained in the aqueous suspension is also provided. | 12-11-2008 |
20090029959 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 01-29-2009 |
20090054387 | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benz- aldehyde (E)-oxime (asoprisnil) - The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.). | 02-26-2009 |
20090054388 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES - The invention provides 11β-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: | 02-26-2009 |
20090062249 | METHODS FOR REDUCING OR PREVENTING TRANSPLANT REJECTION IN THE EYE AND INTRAOCULAR IMPLANTS FOR USE THEREFOR - Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. | 03-05-2009 |
20090075962 | GROWTH STIMULANT COMPOSITIONS - An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection. | 03-19-2009 |
20090118253 | COMPOSITIONS AND METHODS FOR TREATING DYSFUNCTIONAL UTERINE BLEEDING - The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and/or prevention of anemia in patients with dysfunctional uterine bleeding. Compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment. | 05-07-2009 |
20090124589 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 05-14-2009 |
20090124590 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 05-14-2009 |
20090131387 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 05-21-2009 |
20090137543 | METHOD AND COMPOUNDS FOR MODULATING INSULIN PRODUCTION - The present invention provides screening methods for the detection of agents that affect various aspects of β-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect β-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity. | 05-28-2009 |
20090149434 | FORMULATIONS WITH IMPROVED BIOAVAILABILITY, COMPRISING A STEROID DERIVATIVE AND A POLYGLYCOLYSED GLYCERIDE - Compositions comprising a polyglycolysed glyceride, such as GELUCIRE, and a steroid related compound are provided. | 06-11-2009 |
20090176754 | Crystalline Form of the Compound A-348441 - There is provided a hemihydrate of (3β, 5β, 7α, 12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response. | 07-09-2009 |
20090239835 | STABILIZATION OF GLUCOCORTICOID ESTERS WITH ACIDS - The invention relates to nonaqueous pharmaceutical preparations comprising a glucocorticoid ester and an acid, and to the stabilization of glucocorticoid esters in such preparations by acids. | 09-24-2009 |
20090239836 | Multifunctional Ophthalmic Compositions - An multifunctional ophthalmic composition includes a nonionic oxygen-containing polymer and a surfactant. The composition can be used to treat or control ophthalmic diseases, conditions, or disorders. The composition can be a drug delivery vehicle for medicaments having low solubility in water. | 09-24-2009 |
20090264396 | 17Alpha, 21-Dihydroxypregnene esters as antiandrogenic agents - 17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof. | 10-22-2009 |
20100069344 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 03-18-2010 |
20100113408 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS - A compound having the general formula: | 05-06-2010 |
20100144692 | Ulipristal Acetate Tablets - The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: a diluent in an amount of 60 to 95 wt %, a binding agent in an amount of 1 to 10 wt %, croscarmellose sodium in an amount of 1 to 10 wt %, and magnesium stearate in an amount of 0 to 5 wt %. | 06-10-2010 |
20100152147 | Compositions Comprising Azelastine and Methods of Use Thereof - The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and/or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance. | 06-17-2010 |
20100160275 | METHODS AND COMPOSITIONS FOR CANCER PREVENTION AND TREATMENT - The present invention relates to methods and compositions for cancer prevention and treatment. In particular, the present invention provides methods and compositions for modulating, studying, preventing and treating progesterone receptor related carcinogenesis with anti-progesterones and anti-estrogens. | 06-24-2010 |
20100216756 | COMPOSITIONS AND METHODS FOR SUPPRESSING ENDOMETRIAL PROLIFERATION - The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment. | 08-26-2010 |
20100234336 | Ophthalmic Compositions - An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid. | 09-16-2010 |
20100261693 | METHOD FOR TREATING CUSHING'S SYNDROME - The invention relates to a method for treating Cushing's syndrome in a patient, which method comprises administering the patient with a pharmaceutical composition comprising a glucocorticoid receptor antagonist, at least twice a day, or an extended-release composition of a glucocorticoid receptor antagonist, or a combination of a glucocorticoid receptor antagonist and a inhibitor of cortisol synthesis. | 10-14-2010 |
20100273760 | Topical Pharmaceutical Formulations And Methods Of Treatment - In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes. | 10-28-2010 |
20100279993 | Pharmaceutical Propylene Glycol Solvate Compositions - The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. | 11-04-2010 |
20100286107 | Oligomer-Corticosteroid Conjugates - The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer. | 11-11-2010 |
20100286108 | Stabilized Steroid Composition and Method for its Preparation - Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing the isomerization of hydrocortisone 17-butyrate into hydrocortisone 21-butyrate through the use of safflower oil. | 11-11-2010 |
20100298282 | Treatment of Ocular Conditions and the Side-Effects of Glucocorticoids - A compound having glucocorticoid receptor (GR) antagonist activity and a clogP value of less than 5 is useful for the treatment of an ocular condition. Further, a compound having glucocorticoid receptor (GR) antagonist activity is useful, for the treatment of a patient exhibiting side-effects of the administration of a glucocorticosteroid, e.g. wherein the glucocorticosteroid and said compound are administered by different routes. | 11-25-2010 |
20100298283 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY, AND EXTRACT OF PORIA - A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of | 11-25-2010 |
20100311707 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHODS OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder. | 12-09-2010 |
20100324007 | ORAL SUSPENSION OF PREDNISOLONE ACETATE - The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation. | 12-23-2010 |
20110009374 | METHOD OF WOUND HEALING AND SCAR MODULATION - The invention relates to methods of promoting wound healing and reducing scar formation by administration of corticosteroids, and pharmaceutical compositions comprising corticosteroids. | 01-13-2011 |
20110039813 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS - Disclosed are use of a benzophenone derivative represented by general formula (I) or a salt thereof and one or more immunosuppressing agents in combination, and a pharmaceutical composition containing the benzophenone derivative or a salt thereof and one or more immunosuppressing agents. The use and the composition are useful for treatment or prevention of autoimmune diseases and the like. (In the formula, R | 02-17-2011 |
20110046097 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS - The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 02-24-2011 |
20110046098 | PROGESTERONE ANTAGONISTS SUCH AS CDB-4124 IN THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, DYSMENORRHEA, BREAST CANCER, ETC. - The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation. | 02-24-2011 |
20110086828 | TREATMENT OF ALCOHOL ABUSE AND ALCOHOLISM USING MODULATORS OF NEUROSTEROID BINDING SITES ON GABAA RECEPTORS - The present invention provides methods for reducing alcohol drinking behavior in humans and treating acute alcohol poisoning through the use of neutral or negative modulating agents of the neurosteroid sites on GABA | 04-14-2011 |
20110092472 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES - The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. | 04-21-2011 |
20110098260 | Steroid Compounds and Formulations - The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications. | 04-28-2011 |
20110118227 | Methods for the Treatment of Fibromyalgia and Chronic Fatigue Syndrome - The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome. | 05-19-2011 |
20110144077 | TREATMENT OF RETINAL DEGENERATION - The use of a compound having a gon-4-ene nucleus, said nucleus having attached thereto, in the 13 position, a polycarbon-alkyl radical having 2 to about 16 carbon atoms, said compound containing at least 19 and up to 40 carbon atoms in its carbon-carbon skeleton, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells. | 06-16-2011 |
20110207707 | Compounds That Act To Modulate Insect Growth And Methods And Systems For Identifying Such Compounds - Disclosed are methods and systems for screening for compounds that act to modulate insect growth. Bioassays including cell culture and/or transgenic insects engineered with various components of the ecdysoid receptor (EcR) and/or the farsenoid-X receptor (RXR) systems to identify compounds that act as insecticides and/or hormone receptor activators are described. Also described are compounds, and compositions, identified as being putative insecticides based upon their ability to activate EcR and/or FXR mediated transcription. | 08-25-2011 |
20110207708 | Androgen Treatment in Females - The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present invention further is directed to a method of treating a human female with diminished ovarian reserve to improve the female's diminished ovarian reserve. | 08-25-2011 |
20110245216 | USE OF DHEA DERIVATIVES FOR ENHANCING PHYSICAL PERFORMANCE - A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells. | 10-06-2011 |
20110257142 | METHOD FOR PREPARING 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BE- NZALDEHYDE (E)-OXIME (ASOPRISNIL) - The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.). | 10-20-2011 |
20110288061 | Triterpenoid derivatives, benzenoid derivatives and pharmaceutical compositions containing the same - The present invention relates to triterpenoid derivatives, benzenoid derivatives, and pharmaceutical compositions containing the same for treating cancers or inflammatory symptoms. According to the present invention, the triterpenoid derivatives and the benzenoid derivatives are respectively represented by the following formulas (I) and (II): | 11-24-2011 |
20110294771 | TREATMENT OF MUSCULAR DYSTROPHY - The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided. | 12-01-2011 |
20120028947 | Ophthalmic Compositions - An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described. | 02-02-2012 |
20120028948 | TESTOSTERONE GEL AND METHOD OF USE - The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use. | 02-02-2012 |
20120065179 | PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY - There is provided a prodrug of a pharmaceutically active agent, such prodrug comprising a beta-keto carboxylic acid, a beta-keto carboxylic acid salt or a beta-keto carboxylic acid ester functional group, a pharmaceutical composition comprising the prodrug, and to the use of the prodrug or composition for treatment of a mammalian subject suffering from a condition which can be cured or alleviated by administration of the pharmaceutically active agent. There is further provided a method of inhibiting decarboxylation of a compound comprising a beta-keto carboxylic acid or a salt thereof with a monovalent cation, characterized in that a dry salt of the beta-keto carboxylic acid with a divalent or polyvalent cation is prepared. | 03-15-2012 |
20120065180 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION - The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject. | 03-15-2012 |
20120077790 | Ulipristal Acetate Tablets - The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %. | 03-29-2012 |
20120077791 | NOVEL CRYSTALLINE FORM OF ANTIPROGESTIN CDB-4124 - The present invention relates to novel crystalline Form A of 17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124) and methods for the preparation of it in excellent purity. | 03-29-2012 |
20120094969 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception. | 04-19-2012 |
20120094970 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 04-19-2012 |
20120115831 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS - The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible. | 05-10-2012 |
20120129825 | METHOD FOR ON-DEMAND CONTRACEPTION USING LEVONORGESTREL OR NORGESTREL - The invention relates to a method for contraception, which method comprises on-demand administering levonorgestrel or norgestrel in a woman, within 24 hours before an intercourse. | 05-24-2012 |
20120149671 | 17ALPHA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS - 17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3.20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof. | 06-14-2012 |
20120196843 | COMPOSITIONS CONTAINING TOPICAL-ACTIVE AGENTS AND PENTYLENEGLYCOL - Disclosed are cosmetic and dermatological compositions containing hydrocortisone or a derivative thereof, a glycol and a thickening or gelling agent, and methods of making and using them. | 08-02-2012 |
20120238534 | ORAL SUSPENSION OF PREDNISOLONE ACETATE - The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation. | 09-20-2012 |
20120245134 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION - The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject. | 09-27-2012 |
20120283231 | Delivery Of Corticosteroids Through Iontophoresis - Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof. | 11-08-2012 |
20120316146 | ANAESTHETIC FORMULATION - The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof. | 12-13-2012 |
20130018025 | Anticancer CompoundAANM Saifullah;AACI KarachiAACO PKAAGP Saifullah; Karachi PKAANM Khan; SaifullahAACI KarachiAACO PKAAGP Khan; Saifullah Karachi PKAANM Azizuddin;AACI KarachiAACO PKAAGP Azizuddin; Karachi PKAANM Kashif; MuhammadAACI KarachiAACO PKAAGP Kashif; Muhammad Karachi PKAANM Dar; AhsanaAACI KarachiAACO PKAAGP Dar; Ahsana Karachi PKAANM Choudhary; Muhammad IqbalAACI KarachiAACO PKAAGP Choudhary; Muhammad Iqbal Karachi PK - cell suspension culture is used to metabolize dianabol to yield potent anticarcinogenic 17β-hydroxy-17α-methyl-5α-androst-1-en-3-one, which can also be synthesized. | 01-17-2013 |
20130018026 | HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY - The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided. | 01-17-2013 |
20130018027 | COMPOSITIONS AND METHODS FOR NON-TOXIC DELIVERY OF ANTIPROGESTINS - The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation. | 01-17-2013 |
20130023506 | METHOD FOR TREATING UTERINE FIBROIDS - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 01-24-2013 |
20130023507 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 01-24-2013 |
20130023508 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 01-24-2013 |
20130023509 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 01-24-2013 |
20130045959 | METHOD FOR LATE POST COITAL CONTRACEPTION USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse. | 02-21-2013 |
20130079316 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 03-28-2013 |
20130090318 | ONCE-A-MONTH METHOD OF CONTRACEPTION - The invention provides a method for providing contraception in a woman, wherein the woman is administered with a progestogen-only contraception composition once-a-month between the 1 | 04-11-2013 |
20130123226 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). | 05-16-2013 |
20130131030 | OPTIMIZING MIFEPRISTONE ABSORPTION - The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders. | 05-23-2013 |
20130143852 | INFLAMMATORY DISEASE MODEL AND METHOD OF TREATMENT - Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as anti-inflammatory diets and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing reduction in the required anti-inflammatory drug maintenance dose. | 06-06-2013 |
20130143853 | ORAL SUSPENSION OF PREDNISOLONE ACETATE - The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation. | 06-06-2013 |
20130157992 | SUSTAINED DRUG RELEASE AND IMPROVED PRODUCT STABILITY USING NON-COVALENT PARTICLE COATING METHODS - The present invention relates to improved methods of making compositions and compositions made by these methods having improved stability and/or extended release of an active agent or drug upon administration. These compositions may generally comprise an active agent or drug non-covalently immobilized or bound to an excipient substrate. The active agent or drug may include a wide variety of drugs. Binding of the active agent or drug to the substrate may be achieved by evaporating a solvent containing the active agent dissolved therein or by triggering co-precipitation by addition of a precipitating solvent. Additional steps of vacuum removal of surrounding atmosphere and replacement with inert gas may provide additional stability. Present methods and compositions also facilitate manufacturing of drug products and may make these processes safer in some cases. The present invention further provides improved methods of treatment or administration, which may take advantage of improvements with present compositions. | 06-20-2013 |
20130165421 | 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BEN- ZALDEHYDE (E)-OXIME (ASOPRISNIL) - The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.). | 06-27-2013 |
20130190279 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE - The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 07-25-2013 |
20130203721 | TASTE-MASKED POWDER FOR SUSPENSION COMPOSITIONS OF METHYLPREDNISOLONE - A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste-masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients. | 08-08-2013 |
20130274234 | NOVEL 19-NOR-STEROIDS AND THEIR USE FOR TREATING PROGESTERONE- DEPENDENT CONDITIONS - The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation. | 10-17-2013 |
20130324509 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 12-05-2013 |
20130331366 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS - The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible. | 12-12-2013 |
20140005157 | TREATMENT OF UTERINE FIBROIDS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL | 01-02-2014 |
20140005158 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 01-02-2014 |
20140031327 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT - The invention provides inhibitors of α-crystallin aggregation and methods of using α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T | 01-30-2014 |
20140066417 | ANAESTHETIC FORMULATION - The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof. | 03-06-2014 |
20140088058 | SELECTIVE CNS DELIVERY OF MIFEPRISTONE (RU486) TO MODULATE THE TIMING OF THE SPONTANEOUS LH SURGE DURING FOLLICULAR STIMULATION CYCLES - The present invention relates to a new pharmaceutical product containing an antiprogestin molecule, such as mifepristone (RU486), administered by the nasal route and to be used to modulate the timing of the spontaneous LH surge as part of follicular stimulation cycles intended for Assisted Reproductive Technology (ART). In particular, it details the route of administration and the dosages that ensure effective delay of the LH surge without incurring in the antifolliculogenetic effects of the antiprogestinic. It also details the overall treatment method as resulting from the use of the new drug product. | 03-27-2014 |
20140100208 | Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding - Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days. | 04-10-2014 |
20140142077 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION - The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject. | 05-22-2014 |
20140142078 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 05-22-2014 |
20140162992 | Topical application of dihydrotestosterone for promoting hair growth containing formulations - The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals. | 06-12-2014 |
20140162993 | OPTIMIZING MIFEPRISTONE LEVELS IN PLASMA SERUM OF PATIENTS SUFFERING FROM MENTAL DISORDERS TREATABLE WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS - The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL. | 06-12-2014 |
20140187525 | METHOD FOR TREATING UTERINE FIBROIDS - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 07-03-2014 |
20140235602 | Compositions and Methods for Suppressing Endometrial Proliferation - The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment. | 08-21-2014 |
20140235603 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS - The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible. | 08-21-2014 |
20140243299 | Topical Formulations of Corticosteroids with Enhanced Bioavailability - Described herein are methods and compositions for increasing the bioavailability of a corticosteroid, such as hydrocortisone 17-butyrate, in a topical formulation. | 08-28-2014 |
20140243300 | Controlling the Bioavailability of Active Ingredients in Topical Formulations - Described are methods and compositions for tuning the bioavailability of an active agent, such as a corticosteroid, in a topical formulation. | 08-28-2014 |
20140274985 | SYSTEMIC ADMINISTRATION OF ANDROGEN IN TREATING DRY EYE SYNDROME - The present disclosure provides a method for treating dry eye syndrome that comprises systemically administering to a patient in need thereof an effective amount of an androgen, including transdermal or subcutaneous delivery of the androgen. | 09-18-2014 |
20140323454 | ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrn derivative complex of alfaxalone and a bugger, excluding phosphate buffter pH 7.0, 0.1 M mixed as defined in the British Pharmadopoeia 1998, such that the pH of the solution is from 6.0-8.0. | 10-30-2014 |
20140336163 | METHODS OF PRESERVING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN AND A HYDROPHOBIC DRUG - The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products. | 11-13-2014 |
20140343027 | EDIBLE OILS TO ENHANCE DELIVERY OF ORALLY ADMINISTERED STEROIDS - The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient. | 11-20-2014 |
20140364402 | ASSAY FOR SCREENING COMPOUNDS THAT SELECTIVELY DECREASE THE NUMBER OF CANCER STEM CELLS - The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth of the CSC or increases differentiation of the CSC relative to a CSC that has not been contacted with the candidate agent. The method may be used as a high throughput screen. | 12-11-2014 |
20140364403 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 12-11-2014 |
20140378425 | BIOMARKERS FOR DIAGNOSIS OF LUNG DISEASES AND METHODS OF USE THEREOF - The present disclosure provides methods for diagnosis of interstitial lung diseases (ILDs). The present disclosure provides methods for differential diagnosis of idiopathic pulmonary fibrosis from other ILDs. Compositions and kits useful in carrying out a subject method are also provided. | 12-25-2014 |
20150018325 | METHOD FOR LATE POST COITAL CONTRACEPTION USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse. | 01-15-2015 |
20150038476 | Method for Treating Gynecological Diseases - The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical composition suitable for vaginal and/or intrauterine administration comprising a second progesterone receptor modulator. | 02-05-2015 |
20150051180 | Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding - Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days. | 02-19-2015 |
20150065473 | METHOD FOR VISUAL ENHANCEMENT AND POST PROCEDURE TREATMENT PROTOCOL - A new and novel method for determining post procedural treatment is disclosed herein. In one embodiment, a method for a treating a patient following a surgical procedure on at least one eye comprises determining a depth at which the surgical procedure is to be performed or was performed, and providing instructions for administering medication for a length of time to the at least one eye of the patient, the length of time based at least in part upon the depth. | 03-05-2015 |
20150072966 | METHOD OF PROMOTING WOUND HEALING - A method of establishing a therapeutic window of wound fluid nitric oxide (WFNO) in the wound of a mammal, the method including: obtaining a wound fluid sample from a mammal; analyzing the WFNO level; determining whether the WFNO is at or below a lower threshold level, or is at or above an upper threshold level; wherein the lower threshold level and upper threshold level define the therapeutic window of WFNO; and treating the mammal with a substance that alters the WFNO level such that the therapeutic window of WFNO in the wound is established. | 03-12-2015 |
20150094291 | Method and Substance for Improving the Emotional Development of an Infant - The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter. | 04-02-2015 |
20150105361 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE AND POLYCYSTIC LIVER DISEASE - The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell. | 04-16-2015 |
20150111862 | FORMULATIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGESTINS - The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule comprising one or more antiprogestins. | 04-23-2015 |
20150126482 | PHARMACEUTICAL COMPOSITION OR GROUP OF COMPOSITIONS FOR INHIBITING AUTOCRINE HCG PRODUCTION IN ADULT HUMAN CELLS - A pharmaceutical composition for use as medicament that inhibits inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person/body-weight. | 05-07-2015 |
20150133418 | ULIPRISTAL ACETATE FOR PREVENTION AND TREATMENT OF BREAST TUMORS - The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene. | 05-14-2015 |
20150141388 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE - The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 05-21-2015 |
20150148324 | FORMULATIONS FOR THE PREPARATION OF IMMEDIATE RELEASE TABLETS FOR ORAL ADMINISTRATION CONTAINING LOW-DOSE MIFEPRISTONE, TABLETS THUS OBTAINED AND THEIR PREPARATION PROCESS - Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, the tablets thus obtained and their preparation process, are described. | 05-28-2015 |
20150297513 | INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KIDNEY DISEASE AND PREPARATION METHOD THEREOF - The present invention provides an inhalation-type pharmaceutical composition for kidney disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user. | 10-22-2015 |
20150297612 | METHODS AND COMPOSITIONS FOR TREATING PROGESTERONE-DEPENDENT CONDITIONS - The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. Methods for treating these conditions are provided comprising systemically administering an antiprogestin and contemporaneously locally administering an antiprogestin. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation. | 10-22-2015 |
20150297723 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS - The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. | 10-22-2015 |
20150342876 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES - The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease. | 12-03-2015 |
20150359803 | METHODS AND MATERIALS FOR REDUCING SUPRESSION OF IMMUNE FUNCTION - This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14 | 12-17-2015 |
20160009751 | C-19 HYDROXY PREGNENES | 01-14-2016 |
20160022697 | METHOD FOR SCHEDULING OVULATION - The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase. | 01-28-2016 |
20160022698 | METHOD FOR TREATING UTERINE FIBROIDS - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 01-28-2016 |
20160074513 | Long-Acting Semi-Solid Lipid Formulations - What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition. | 03-17-2016 |
20160113943 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 04-28-2016 |
20160116493 | Lp(a) SUBFORM SIZE IDENTIFICATION USING ELISA - The application describes methods for determining the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample using enzyme linked immunosorbent assay (ELISA). The methods described herein significantly improve lipoprotein ELISA methods and devices capable of quantifying particle numbers and population mass of Lp(a) particles. This technology offers a method for the efficient and cost-effective measurement of specific Lp(a) in a rapid, low-cost format, rather than limited measurement of Lp(a) concentration in patient tissues. The ability to measure the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample also provides a useful diagnostic tool for assessing cardiovascular risk in a subject. | 04-28-2016 |
20160120879 | USE OF SUSTAINED RELEASE DEXAMETHASONE IN POST-CATARACT SURGERY INFLAMMATION - The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery | 05-05-2016 |
20160129016 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 05-12-2016 |
20160145692 | METHODS AND COMPOSITIONS INVOLVING LINCRNA AND LEUKEMIA - The instant disclosure relates to the finding that lincRNA expression is associated with particular cytogenetic abnormalities and is related to disease pathogenesis of certain cancers. Long intergenic non-coding RNAs (lincRNAs) have been found to play a role in gene regulation, but their expression has not been described in B acute lymphoblastic leukemia (B-ALL). Methods and compositions are provided regarding B-ALL associated long intergenic RNAs (BALIRs). | 05-26-2016 |
20160166583 | ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODS | 06-16-2016 |
20160184431 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID - Topical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol. | 06-30-2016 |
20160250230 | THERMO-KINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS | 09-01-2016 |
20160375037 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of diseases. | 12-29-2016 |
20190145979 | METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTI-PROGESTIN SENSITIVE TUMORS | 05-16-2019 |